[HTML][HTML] Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - cell.com
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - pubmed.ncbi.nlm.nih.gov
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - europepmc.org
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - infona.pl
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
[PDF][PDF] Anti-Ab Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - core.ac.uk
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid b-peptide (Ab) production, aggregation, or accumulation. Translational models …
amyloid b-peptide (Ab) production, aggregation, or accumulation. Translational models …
[HTML][HTML] Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - Elsevier
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
amyloid β-peptide (Aβ) production, aggregation, or accumulation. Translational models …
[引用][C] Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - cir.nii.ac.jp
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[HTML][HTML] Anti-Aβ therapeutics in Alzheimer's disease: The Need for a Paradigm Shift
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - ncbi.nlm.nih.gov
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
TE Golde, LS Schneider, EH Koo - Neuron, 2011 - europepmc.org
Most current Alzheimer's disease (AD) therapies in advanced phases of development target
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …
amyloid beta-peptide (Aβ) aggregation and accumulation. Translational models suggest that …